Company: ARMP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077648
Chunk: 14

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 14
---
 Inc.
was converted to a limited liability company organized under the laws of the State of California named C3 Jian, LLC. Prior to the Merger,
C3J was privately held and was financed principally through a series of equity financings.

AmpliPhi was incorporated
under the laws of the State of Washington in March 1989 as a wholly-owned subsidiary of Immunex Corporation and began operations
as an independent company in 1992 as Targeted Genetics Corporation. In January 2011, AmpliPhi completed the acquisition of Biocontrol
Ltd, an antimicrobial biotechnology company based in the United Kingdom, with the goal of developing their phage therapy programs using
funding from the sale of our legacy gene therapy assets. In November 2012, AmpliPhi completed the acquisition of Special Phage Holdings
Pty Ltd, a company based in Australia, with the goal of continuing research addressing the rapidly escalating problem of antibiotic resistance
through the development of a series of bacteriophage-based treatments.

<div align='center'>5</div>

Pipeline The following chart summarizes the status of our phage product candidate development programs and partners: Risks Associated with Our Business and this Offering Our business and our ability to implement our business strategy are subject to numerous risks, as more fully described in the section of this prospectus entitled “Risk Factors.” You should read these risks before you invest in our securities. We may be unable, for many reasons, including those that are beyond our control, to implement our business strategy. In particular, risks associated with our business include:

| · | There is substantial doubt about our ability                                                                                            
 to continue as a going concern, which may affect our ability to obtain future financing and may require us to curtail our operations.   
 We will need substantial additional financing to develop our product candidates and implement our operating plans, including to support 
 one or more pivotal trials in 2025 and beyond. If we fail to obtain additional financing, we may be delayed or unable to complete the   
 development and commercialization of our product candidates.                                                                            |

| · | We have incurred losses since our inception and                                                                                     
 anticipate that we will continue to incur significant losses for the foreseeable future, and our future profitability is uncertain. |

| · | If we fail to develop and maintain proper and                                                                                         
 effective processes and operating procedures as a non-traditional government contractor, our ability to adhere to the DoD and related 
 entity standards could impact our ongoing and future development financing awards from the U.S. government;